This week, the Office of Inspector General (OIG) for the Department of Health and Human Services (HHS) released a report on Medicare Part B drug payments. Currently, physicians are reimbursed for drugs administered in the office at the average sales price (ASP) plus 6%. However, if the average manufacturer’s price (AMP) is determined to be at least 5% lower than ASP, CMS is required to reimburse physicians at the lower AMP rate. The report compared the ASP with the AMP of drugs and found that CMS lowered Part B drug reimbursement rates for 14 drugs, saving Medicare beneficiaries and the program $24 million in CY2014. In addition, OIG estimated that if CMS expanded the price-substitution policy, there would be $9 million in additional savings.